Top Markets
Coin of the day
NewcelX Ltd. NewcelX Ltd.

NewcelX Ltd.

NCEL
Rank in Stocks #37735
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich,... NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Share Price
$3.29
Last synced: 2026-08-14
Market Cap
$1.48M
Change (1 day)
-8.63%
Change (1 year)
-86.89%
Country
CH
Trade NewcelX Ltd. (NCEL)

Category

P/E ratio for NewcelX Ltd. (NCEL)
P/E ratio as of 2026 TTM: 0
According to NewcelX Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for NewcelX Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.05 -
US
31.14 -
NL
- -
CH
- -
KR
19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.